The a2 Milk Company (ASX:A2M) is no longer asking investors to look only at infant formula.
That is still the core business. It remains the profit engine, the China anchor and the reason the company is on most ASX watchlists. But the more interesting part of the story is now sitting one step away from the baby-formula aisle: kids nutrition, seniors products, paediatric supplements, liquid milk and a tighter hold over manufacturing.
The question is not whether A2M has demand. Its own recent updates suggest demand is still there. The question is whether the company can turn that demand into delivered product, clean margins and steadier earnings.
A2M is trying to stretch the brand across life stages
A2M’s FY25 result showed why management has started talking beyond infant formula. The company reported record FY25 revenue of NZ$1.902 billion, up 13.5%, with EBITDA up 17.1% to NZ$274.3 million and NPAT up 21.1% to NZ$202.9 million. It also said it had reached a top-four brand position in China’s infant milk formula market.
That gives the new product story some weight. In FY25, A2M launched products across infant, kids and seniors nutrition, and entered the Vietnam infant milk formula market. By 1H26, the company said Other Nutritionals revenue had grown 42.9%, helped by kids and seniors products, entry into paediatric supplements and a new kids fortified UHT product planned for launch in 2H26.
The interest point is simple. A2M is trying to make the a2 brand useful for more than one purchase window in a household’s life.
That is a cleaner growth story than relying only on birth rates and formula market share. It also puts more pressure on execution because each extra category adds complexity.
China is still the prize, and still the pressure point
China remains the centre of the A2M story. In 1H26, infant milk formula revenue rose 13.6%, with English label IMF up 20.9% and China label IMF up 6.5%. The company also reported China and Other Asia segment revenue growth of 20.3%.
Management’s message in February was confident. It upgraded FY26 guidance and said A2M was on track to reach its NZ$2 billion medium-term sales ambition in FY26, a year ahead of plan.
Then April made the story messier.
On 13 April 2026, A2M said demand across product categories and regions remained strong in 3Q26, with China label demand supported by new user recruitment, a My Little Pony campaign and its new kids nutrition product. But it also flagged product availability issues in China label infant formula, linked to demand, freight, production backlogs, product-release testing and customs clearance.
The market does not usually mind strong demand. It does mind when strong demand cannot be supplied.
Pōkeno is the strategic hinge
The company’s supply chain changes are not just back-office housekeeping. They sit at the centre of the next phase.
In August 2025, A2M announced the acquisition of an integrated nutritional manufacturing facility in Pōkeno, New Zealand, from Yashili New Zealand Dairy Co. for about NZ$282 million. It also announced the sale of its 75% stake in Mataura Valley Milk, with expected net proceeds of about NZ$100 million and an expected loss on sale of about NZ$130 million.
The strategic logic is clear enough. Pōkeno gives A2M access to China label registrations, more control over manufacturing and a platform for product expansion. The company said it intended to invest about NZ$100 million in a multi-year programme to increase capacity and capability at the site.
That makes Pōkeno more than an asset purchase. It is the factory behind the broader brand story.
The risk is that investors have already seen what happens when supply is tight. In April, A2M said its Pōkeno programme remained on track, including capital works, recruitment, product trials and the China label registration amendment process, ahead of expected production ramp-up in 1H27.
That ramp-up now matters more than the slogan.
The product story is good. The timing is less comfortable
There is a supportive reading of A2M’s position. Demand appears healthy. The brand still has traction in China. New nutrition categories are growing off a smaller base. The company has a large cash position, with NZ$896.9 million at 31 December 2025, and it has begun paying dividends.
There is also a more cautious reading. A2M cut its FY26 outlook in April after the supply chain issues. It moved revenue growth guidance to low-to-mid double digit from mid double digit, lowered expected EBITDA margin to 14.0% to 14.5% from 15.5% to 16.0%, and reduced cash conversion guidance to about 50% from 80%.
That is the tension in the stock. A2M is building a broader growth platform, but the next proof point is not a new product launch. It is delivery.
What investors may watch next
The key update is likely to be how much of the April disruption was timing and how much became lost sales. Investors may also watch the Pōkeno production ramp, the China label registration process, margins after one-off costs, and whether Other Nutritionals can keep growing without being treated as a side story.
A2M does not need to prove that the brand can travel. It has already started to show that. It needs to prove that the operating system behind the brand can keep up.
